HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G’s String Of Cosmetic Brand Tuck-Ins Questioned During Q2 Call

Executive Summary

Procter & Gamble says it has catapulted recently acquired brands including First Aid Beauty and Native in a way that few know how, without compromising their unique character. While confident in the futures of those brands and others joining the company – mainly skin care – P&G will change direction as needed, executive leadership said.

You may also be interested in...



China Lockdown Offsets P&G Sales Growth Across Product Categories In All Other Regions

Soaring beauty sales in North America, Europe and Latin America were offset by double-digit decline in greater China due to COVID-19 lockdowns. To offset supply chain problems, firm plans to invest in manufacturing in North America and Europe.

Bodewell OTC Eczema, Psoriasis Treatments Relaunched After P&G Ventures’ Acquisition

The line, using colloidal oatmeal for eczema, salicylic acid for psoriasis or pyrithione zinc for flaky scalp, was independently launched in beta by a Vancouver, BC, start-up in January 2020 and debuted in May that year.

P&G Widens Pricing Strategy To At Least 60% Of Products As Costs Soar

Procter & Gamble’s pricing strategy now impacts 10 of its US product categories, with action also being taken broadly in non-US markets. President and CEO Jon Moeller calls this pricing "at a different level" historically speaking, and warns there will be ‘bumps in the road." But P&G is confident in its long track record and raises full-year guidance accordingly.

Related Content

Topics

UsernamePublicRestriction

Register

RS152134

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel